Professor Chad Mirkin found that the vaccine’s carefully organized structure dramatically boosts cancer-fighting immunity.

The findings will be published today (February 11) in Science Advances.

If proven effective in humans, the vaccine could complement standard therapies for HPV-driven cancer, as well as inform the design of therapeutic vaccines for other diseases.

Explore how HPV tumours are targeted by innovative vaccine designs that enhance immune response against cancer effectively.

A structurally tuned HPV cancer SNA vaccine boosts CD8⁺ T‑cell responses and slows tumor growth in mice and patient‑derived spheroids, a study shows.

The vaccine against human papillomavirus, or HPV, has reduced cervical cancer by nearly 90% in women vaccinated as ...